HomeAI · summaries
Storia in 3 fonti
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new…
- ·
endpoints.news
Summit reports two-year survival data for Western patients, though context lacking
Summit's ivonescimab cuts death risk 24% (HR 0.76) in Western NSCLC patients at the 2-year HARMONi mark, but median survival figures remain undisclosed.
